Efficacy and Safety of Co-administered Cagrilintide and Semaglutide (CagriSema) 2.4 mg/2.4 mg s.c. Once Weekly Versus Tirzepatide 15 mg s.c. Once Weekly in Participants With Type 2 Diabetes Inadequately Controlled on Metformin With or Without an SGLT2 Inhibitor
Efficacy and Safety of Co-administered Cagrilintide and Semaglutide (CagriSema) 2.4 mg/2.4 mg s.c. Once Weekly Versus Tirzepatide 15 mg s.c. Once Weekly in Participants With Type 2 Diabetes Inadequately Controlled on Metformin With or Without an SGLT2 Inhibitor
This study will look at how well CagriSema helps people with type 2 diabetes lower their blood sugar and body weight. CagriSema is a new investigational medicine. Doctors may not yet prescribe CagriSema. CagriSema will be compared to a medicine called tirzepatide that doctors may prescribe in some countries. Participants will get either CagriSema or tirzepatide. Which treatment participant get is decided by chance like flipping a coin. Participant will have an equal chance of receiving either drug. For each participant, the study will last for up to one and a half years.
Inclusion Criteria:
Exclusion Criteria:
Ciudad Autonoma de Buenos Aires, Buenos Aires C1061AAE, Argentina
Ciudad Autonoma de Buenos Aires, Buenos Aires C1405BUB, Argentina
Ciudad de Buenos Aires, Buenos Aires C1405CWB, Argentina
CABA, C1060ABA, Argentina
CABA, C1060ABA, Argentina
Parkville, Victoria 3050, Australia
Bogotá, 110221, Colombia
Thiruvnanthapuram, Kerala 695033, India
Aligarh, 202002, India
Thriruvananthapuram, 695 032, India